Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study
Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study
复制标题
DOI：
10.1186/s12885-019-5989-2
复制
发表时间：
2019-08-13
期刊：
影响因子：
3.8
通讯作者：
Piscaglia, Fabio
中科院分区：
文献类型：
--
作者：
Miksad, Rebecca A.;Ogasawara, Sadahisa;Piscaglia, Fabio
背景经动脉化疗栓塞术（TACE）后慢性肝损伤的真实发生率尚不清楚。LiverT是一项回顾性、观察性研究，评估了美国实践中真实世界肝细胞癌（HCC）患者单次TACE后的肝功能恶化。方法使用标准代码从Optum的综合数据库中识别出符合条件的HCC患者，这些患者在2010年至2016年期间接受了索引TACE，并且在随后的3个月内没有接受额外的肿瘤治疗。在基线时需要至少一个实验室值（胆红素、白蛋白、天冬氨酸转氨酶[AST]、丙氨酸转氨酶[ALT]、国际标准化比值[INR]），急性（
Background The real-world incidence of chronic liver damage after transarterial chemoembolization (TACE) is unclear. LiverT, a retrospective, observational study, assessed liver function deterioration after a single TACE in real-world hepatocellular carcinoma (HCC) patients in US practice. Methods Eligible HCC patients identified from Optum's integrated database using standard codes as having had an index TACE between 2010 and 2016 with no additional oncologic therapy in the subsequent 3 months. At least one laboratory value (bilirubin, albumin, aspartate transaminase [AST], alanine transaminase [ALT], international normalized ratio [INR]) was required at baseline and the acute (